Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence

BMC Research Notes

Volumn 4, Issue , 2011, Pages

  Namujju, Proscovia B ^a,b,c   Hedman, Lea ^d   Hedman, Klaus ^d   Banura, Cecily ^e   Mbidde, Edward K ^b   Kizito, Dennison ^b   Byaruhanga, Romano N ^f,g   Muwanga, Moses ^h   Kirnbauer, Reinhard ⁱ   Surcel, Heljä Marja ^a   Lehtinen, Matti ^c  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

^e MAKERERE UNIVERSITY   (Uganda)

^f San Raphael of St Francis Hospital   (Uganda)

^g KAROLINSKA INSTITUTE   (Sweden)

^h Entebbe Hospital   (Uganda)

ⁱ Universitatsklinik fur Dermatologie   (Austria)

Author keywords

antibody; avidity; genital infection; HPV; prevalence

Indexed keywords

BACTERIA (MICROORGANISMS); HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 79957901159     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-4-170     Document Type: Article

References (31)

1. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. J Ferlay F Bray P Pisani MD Parkin, IARC Cancer Base IARC, Lyon 2.0 2004
2. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. JM Walboomers MV Jacobs MM Manos FX Bosch JA Kummer KV Shah PJ Snijders J Peto CJ Meijer N Mũoz, J Pathol 1999 189 12 9 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482 (Pubitemid 29406813)
3. Risk factors subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus like particles. GY Ho Y Studentsov R Bierman L Beardsley M Lempa RD Burk, J Infect Dis 2002 186 737 42 10.1086/342972 12198606 (Pubitemid 35013424)
4. Human papillomavirus infections with multiple types and risk of cervical neoplasia. H Trottier S Mahmud MC Costa JP Sobrinho E Duarte-Franco ET Rohan A Ferenczy LL Villa EL Franco, Cancer Epidemiol Biomarkers Prev 2006 15 1274 80 10.1158/1055-9965.EPI-06-0129 16835323 (Pubitemid 44125281)
5. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. DR Brown SK Kjaer K Sigurdsson OE Iversen M Hernandez-Avila CM Wheeler G Perez LA Koutsky EH Tay P Garcia, et al. J Infect Dis 2009 199 926 35 10.1086/597307 19236279
6. Efficacy of human papillomavirus (HPV)-16/18AS04-adjuvanted vaccine against cervical infection andprecancer caused by oncogenic HPV types (PATRICIA):final analysis of a double-blind, randomised study inyoung. J Paavonen P Naud J Salmerán CM Wheeler SN Chow D Apter H Kitchener X Castellsague JC Teixeira SR Skinner, et al. Lancet 2009 374 301 14 10.1016/S0140-6736(09)61248-4 19586656
7. Prophylactic use of human papillomavirus (HPV) L1 virus-like particle vaccine significantly reduces intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ risk. L Villa G Perez S Kjaer M Lehtinen J Paavonen N Munoz K Sigurdsson M Hernandez-Avila OE Iversen S Thoresen, et al. Lancet 2007 369 1861 8 10.1016/S0140-6736(07)60852-6 17544766
8. High prevalence of HPV among female students in Finland. E Auvinen M Niemi C Malm R Zilliacus A Trontti R Fingerroos M Lehtinen J Paavonen, Scand J Infect Dis 2005 37 873 6 10.1080/00365540500333566 16308223
9. Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda. C Banura S Franceschi LJ van Doorn A Arslan B Kleter F Wabwire-Mangen EK Mbidde W Quint E Weiderpass, Int J Cancer 2008 123 2180 7 10.1002/ijc.23762 18711697
10. Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan women. PB Namujju HM Surcel R Kirnbauer M Kaasila C Banura R Byaruhanga M Muwanga EK Mbidde P Koskela M Lehtinen, Scand J Infect Dis 2010 42 522 6 10.3109/00365540903582426 20180681
11. Prerequisites for human papillomavirus vaccine trial: results of feasibility studies. J Paavonen M Halttunen BG Hansson P Nieminen R Rostila M Lehtinen, J Clin Virol 2000 19 25 30 10.1016/S1386-6532(00)00130-X 11091145
12. The serological response to papillomaviruses. J Dillner, Sem Cancer Biol 1999 9 423 30 10.1006/scbi.1999.0146 (Pubitemid 30184512)
13. Identification of human papillomavirus seroconversions. A Wikstrom GJJ Van Doornum WGV Quint JT Schiller J Dillner, J Gen Virol 1995 76 529 39 10.1099/0022-1317-76-3-529 7897345
14. The role of antibody concentration and avidity in antiviral protection. MF Bachmann U Kalinke A Althage G Freer C Burkhart H Roost M Aguet H Hengartner RM Zinkernagel, Science 1997 276 2024 7 10.1126/science.276.5321.2024 9197261 (Pubitemid 27443603)
15. + T-cell help. Y Nakanishi Lu Bao C Gerard A Lwasaki, Nature 2009 462 510 3 10.1038/nature08511 19898495
16. Co-receptors of B lymphocytes. L O'Rourke R Tooze DT Fearon, Curr Opin Immunol 1997 9 324 9 10.1016/S0952-7915(97)80077-5 9203413 (Pubitemid 27303500)
17. Recent primary toxoplasma infection indicated by a low avidity of specific IgG. K Hedman M Lappalainen I Seppala O Makela, J Infect Dis 1989 159 736 40 10.1093/infdis/159.4.736 2926163 (Pubitemid 19105628)
18. Measurement of avidity of specific IgG for verification of recent primary rubella. K Hedman SA Rousseau, J Med Virol 1989 27 288 92 10.1002/jmv. 1890270406 2723615 (Pubitemid 19125783)
19. Immunoglobulin G avidity in the serodiagnosis of congenital rubella syndrome. V Herne K Hedman P Reedik, Eur J Clin Microbiol Infect Dis 1997 16 763 6 10.1007/BF01709262 9405951 (Pubitemid 27496749)
20. Accurate serodiagnosis of B19 Parvovirus by measurement of IgG avidity. M Soderlund CS Brown BJ Cohen K Hedman, J Infect Dis 1995 14 354 61 10.1097/00006454-199505000-00004
21. Avidity of IgG antibodies distinguishes primary from non-primary cytomegalovirus infections in pregnant women. M Bodeus S Feyder P Goubau, Clin Diag Virol 1998 9 9 16 10.1016/S0928-0197(97)10016-2 (Pubitemid 28153242)
22. Delayed acquisition of high avidity anti-cytomegalovirus antibody is correlated with prolonged antigenemia in solid organ transplant receipts. T Lazzarotto S Varani P Spezzacatens P Praadelli L Poteni A Lombardi V Ghasetti L Gabrielli AD Abate C Magelli PM Landini, J Infect Dis 1998 178 1145 9 10.1086/515671 9806047 (Pubitemid 28452211)
23. Antipeptide IgA antibodies to a human papillomavirus type 16 E2 derived synthetic peptide predict the natural history of cervical HPV infection. M Lehtinen P Parkkonen H Luoto A Ylä-Outinen U Romppanen I Rantala J Paavonen, Serono Symposia Pub 1990 78 509 19
24. Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s. M Lehtinen M Kaasila K Pasanen T Patama J Palmroth P Laukkanen E Pukkala P Koskela, Int J Cancer 2006 119 11 2612 9 10.1002/ijc.22131 16991128 (Pubitemid 44691316)
25. Seropositivities to human papillomavirus types 16,18 or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Dillner I Kallings C Brihmer B Sikström P Koskela M Lehtinen JT Schiller M Sapp PA Mardh, J Infect Dis 1996 173 1394 8 10.1093/infdis/173.6.1394 8648211 (Pubitemid 26286798)
26. Natural seroconversion to high risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. J Palmroth P Namujju A Simen-Kapeu V Kataja HM Surcel M Tuppurainen M Yliskoski K Syrjänen M Lehtinen, Scand J Inf Dis 2010 42 379 84 10.3109/00365540903501608
27. Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection. A Simen-Kapeu V Kataja M Yliskoski K Syrjänen J Dillner P Koskela J Paavonen M Lehtinen, Scand J Infect Dis 2008 40 745 51 10.1080/00365540801995360 19086247
28. Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population based case-control study. L Kjellberg Z Wang F Wiklund K Edlund T Angstrom P Lenner I Sjoberg G Hallmans KL Wallin M Sapp J Schiller G Wadell CG Mahlck J Dillner, J Gen Virol 1999 80 391 8 10073699 (Pubitemid 29095199)
29. Population dynamics of serologically defined infections with HPV11/16/18/31 in fertile-aged women. M Kaasila P Koskela R Kirnbauer E Pukkala H-M Surcel M Lehtinen, Int J Cancer 2009 25 2166 77
30. Immunoglobulin class switching. J Stavnezer, Curr Opin Immunol 1996 8 199 205 10.1016/S0952-7915(96)80058-6 8725943 (Pubitemid 26166985)
31. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. JG Dauner Y Pan A Hildesheim C Harro LA Pinto, Vaccine 2010 28 5407 13 10.1016/j.vaccine. 2010.06.018 20591543